These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 30753495

  • 1. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
    Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E.
    J Antimicrob Chemother; 2019 May 01; 74(5):1300-1305. PubMed ID: 30753495
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
    Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE.
    Clin Infect Dis; 2012 Apr 01; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of oritavancin and nisin alone and their combination against vancomycin resistant enterococci strains in hospitalized patients in Turkiye.
    Sefali S, Y N.
    Indian J Med Microbiol; 2024 Apr 01; 47():100489. PubMed ID: 37890415
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF, Seguin DL, Belley A, Moeck G.
    Diagn Microbiol Infect Dis; 2017 Oct 01; 89(2):168-171. PubMed ID: 28733126
    [Abstract] [Full Text] [Related]

  • 13. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.
    Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN.
    Antimicrob Agents Chemother; 2012 Mar 01; 56(3):1639-42. PubMed ID: 22183169
    [Abstract] [Full Text] [Related]

  • 14. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    Carter GP, Harjani JR, Li L, Pitcher NP, Nong Y, Riley TV, Williamson DA, Stinear TP, Baell JB, Howden BP.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1562-1569. PubMed ID: 29518208
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
    Belley A, Lalonde-Séguin D, Arhin FF, Moeck G.
    Antimicrob Agents Chemother; 2017 Oct 01; 61(10):. PubMed ID: 28784674
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF.
    Int J Antimicrob Agents; 2015 Dec 01; 46(6):674-81. PubMed ID: 26541881
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.
    Dahesh S, Wong B, Nizet V, Sakoulas G, Tran TT, Aitken SL.
    Antimicrob Agents Chemother; 2019 Jul 01; 63(7):. PubMed ID: 31235559
    [Abstract] [Full Text] [Related]

  • 19. Characterization of clinical enterococci isolates, focusing on the vancomycin-resistant enterococci in a tertiary hospital in China: based on the data from 2013 to 2018.
    Zhou W, Zhou H, Sun Y, Gao S, Zhang Y, Cao X, Zhang Z, Shen H, Zhang C.
    BMC Infect Dis; 2020 May 19; 20(1):356. PubMed ID: 32517758
    [Abstract] [Full Text] [Related]

  • 20. In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci.
    Tong J, Jiang Y, Xu H, Jin X, Zhang L, Ying S, Yu W, Qiu Y.
    Drug Des Devel Ther; 2021 May 19; 15():3049-3055. PubMed ID: 34285472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.